Skip to content

Fact Sheet

About Illumina

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.

We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Quick Facts
  • Website:
    www.illumina.com
  • Ticker symbol:
    ILMN
  • Headquarters:
    San Diego, California, USA
  • Number of employees:
    >7,300 globally
  • 2018 revenue:
    $3.3 Billion USD
  • Illumina @ A Glance
    Fact Sheet

The Illumina mission

We take our mission seriously and engrain it in everything we do.

Our mission statement:
To improve human health by unlocking the power of the genome.

Leading-edge products and services

Illumina has developed a comprehensive line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. Our broad portfolio of leading-edge sequencing and array-based solutions address a range of genomic complexity and throughput, enabling researchers to select the best solution for their scientific challenge.

Instruments

  • NovaSeq Sequencing Systems
  • NextSeq Sequencing Systems
  • NextSeqDX Sequencing System
  • MiSeq Sequencing System
  • MiSeqDx Sequencing System
  • MiniSeq Sequencing System
  • iSeq 100 System
  • iScan Array Scanner

Assays

  • AmpliSeq for Illumina
  • TruSeq, TruSight, and Nextera technologies
  • Sequencing by synthesis chemistry
  • Infinium genotyping and methylation assays

Where we operate

  • San Diego, California, USA
  • Foster City, California, USA
  • Madison, Wisconsin, USA
  • São Paulo, Brazil
  • Évry, France
  • Cambridge, UK
  • Eindhoven, Netherlands
  • Beijing, China
  • Shanghai, China
  • Singapore
  • Osaka, Japan
  • Tokyo, Japan
  • Seoul, South Korea
  • Melbourne, Australia

Illumina Management Team

  • Francis deSouza
    President & Chief Executive Officer
  • Charles Dadswell
    Senior Vice President & General Counsel
  • Dave Daly
    Senior Vice President & General Manager, Commercial Operations—Americas
  • Paula Dowdy
    Senior Vice President & General Manager, Commercial Operations—Europe, Middle East and Africa
  • Garret Hampton
    Senior Vice President, Clinical Genomics
  • Aimee Hoyt
    Senior Vice President & Chief People Officer
  • Omead Ostadan
    Senior Vice President, Products, Marketing & Strategic Planning
  • Li Qing
    Vice President and General Manager, Greater China
  • Bob Ragusa
    Senior Vice President, Global Quality & Operations
  • Mostafa Ronaghi, PhD
    Senior Vice President & Chief Technology Officer
  • Sam Samad
    Senior Vice President & Chief Financial Officer
  • Mark Van Oene
    Senior Vice President & Chief Commercial Officer
  • Gretchen Weightman
    Vice President & General Manager—Asia Pacific & Japan